The stock of Mainz Biomed N.V (MYNZ) has seen a 0.74% increase in the past week, with a -28.54% drop in the past month, and a -43.21% decrease in the past quarter. The volatility ratio for the week is 23.91%, and the volatility levels for the past 30 days are at 15.68% for MYNZ. The simple moving average for the last 20 days is -13.07% for MYNZ stock, with a simple moving average of -62.94% for the last 200 days.
Is It Worth Investing in Mainz Biomed N.V (NASDAQ: MYNZ) Right Now?
The 36-month beta value for MYNZ is at 0.09. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MYNZ is 17.46M, and currently, shorts hold a 8.69% of that float. The average trading volume for MYNZ on November 18, 2024 was 3.14M shares.
MYNZ) stock’s latest price update
Mainz Biomed N.V (NASDAQ: MYNZ)’s stock price has decreased by -9.26 compared to its previous closing price of 0.24. However, the company has seen a 0.74% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-21 that Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V.
Analysts’ Opinion of MYNZ
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MYNZ reach a price target of $25. The rating they have provided for MYNZ stocks is “Buy” according to the report published on June 21st, 2022.
MYNZ Trading at -18.69% from the 50-Day Moving Average
After a stumble in the market that brought MYNZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.90% of loss for the given period.
Volatility was left at 15.68%, however, over the last 30 days, the volatility rate increased by 23.91%, as shares sank -22.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.59% lower at present.
During the last 5 trading sessions, MYNZ rose by +3.95%, which changed the moving average for the period of 200-days by -74.46% in comparison to the 20-day moving average, which settled at $0.2495. In addition, Mainz Biomed N.V saw -81.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MYNZ
Current profitability levels for the company are sitting at:
- -31.23 for the present operating margin
- 0.57 for the gross margin
The net margin for Mainz Biomed N.V stands at -30.58. The total capital return value is set at -3.27.
Based on Mainz Biomed N.V (MYNZ), the company’s capital structure generated 0.65 points at debt to capital in total, while cash flow to debt ratio is standing at -2.73.
Currently, EBITDA for the company is -25.01 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 7.94. The receivables turnover for the company is 1.82for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
In conclusion, Mainz Biomed N.V (MYNZ) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
